A Phase I, Open-Label, Randomised, Balanced, Single-Dose, Two-Period, Two-Sequence Crossover-Design Study to Evaluate Effects of Food on the Bioavailability of 80 mg Elafibranor (IPN60190) To-be-marketed Tablet Formulation After Single Oral Administration in Healthy Adult Participants
Latest Information Update: 23 Jul 2023
At a glance
- Drugs Elafibranor (Primary)
- Indications Primary biliary cirrhosis
- Focus Pharmacokinetics
- Sponsors Ipsen
Most Recent Events
- 26 Jan 2023 Status changed from active, no longer recruiting to completed.
- 20 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 17 Nov 2022 Status changed from not yet recruiting to recruiting.